Luye Pharma’s new drug LY03010 for the treatment of schizophrenia and schizoaffective disorders has obtained ...
Luye Pharma has announced the acquisition of two investigational biological antibodies being developed by Shan...
Luye Pharma grants AstraZeneca exclusives rights to promote Xuezhikang Capsules in mainland China
Luye Pharma Group has announced that its CNS drug, Seroquel XR, has received approval from the official Chines...
A China Class 1 New Compound Starting Phase I Clinical Trials
Luye Pharma s independently developed drug LY01005 has entered phase III clinical trials for prostate cancer ...
TOP